AtriCure Inc (ATRC.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AtriCure Inc raises FY 2014 revenue guidance; reaffirms FY 2014 EBITDA guidance


Thursday, 24 Jul 2014 04:07pm EDT 

AtriCure Inc:Projects FY 2014 revenue will be in the range of $103 million to $105 million.This compares to previous expectations of FY 2014 revenue in the range of $101 million to $104 million.Says consistent with guidance provided in Feb., adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $9 million to $10 million for FY 2014, of which about $3.5 million of expense will be related to the Estech transaction.FY 2014 revenue of $102.57 million- Thomson Reuters I/B/E/S. 

Company Quote

14.39
0.04 +0.28%
4:00pm EDT